^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCR4 mutation

    i
    Other names: CXCR4, CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R, Chemokine (C-X-C motif) receptor 4
    Entrez ID:
    7852
    Related biomarkers:
    Expression
    Mutation
    Apply
    Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1) (NCT05099471)
    Phase 2
    University of Ulm
    Not yet recruiting
    Last update posted :
    05/13/2024
    Initiation :
    09/01/2024
    Primary completion :
    10/01/2027
    Completion :
    10/01/2032
    MYD88 • CXCR4
    |
    CXCR4 mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cyclophosphamide • cyclophosphamide intravenous
    Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia (NCT02677324)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    05/11/2022
    Initiation :
    05/09/2016
    Primary completion :
    02/14/2020
    Completion :
    02/07/2022
    BCL2 • CXCR4
    |
    CXCR4 mutation
    |
    Venclexta (venetoclax)
    Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia (NCT02400437)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    09/02/2020
    Initiation :
    04/01/2015
    Primary completion :
    11/01/2019
    Completion :
    11/01/2019
    MYD88 • CXCR4
    |
    MYD88 L265P • CXCR4 mutation
    |
    Rituxan (rituximab) • Ninlaro (ixazomib)